163 related articles for article (PubMed ID: 37833904)
1. The Prognostic Significance of Selected HLA Alleles on Prostate Cancer Outcome.
Stokidis S; Baxevanis CN; Fortis SP
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833904
[TBL] [Abstract][Full Text] [Related]
2. HLA Class I Allele Expression and Clinical Outcome in De Novo Metastatic Prostate Cancer.
Stokidis S; Fortis SP; Kogionou P; Anagnostou T; Perez SA; Baxevanis CN
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32570992
[TBL] [Abstract][Full Text] [Related]
3. The clinical significance of perineural invasion in patients with de novo metastatic prostate cancer.
Zhao J; Chen J; Zhang M; Tang X; Sun G; Zhu S; Liu J; Zhang H; Zhang X; Yin X; Zhao P; Zhu X; Ni Y; Dai J; Shen P; Chen N; Zeng H
Andrology; 2019 Mar; 7(2):184-192. PubMed ID: 30609313
[TBL] [Abstract][Full Text] [Related]
4. [The subgroup analysis of the prognostic value of the intraductal carcinoma of the prostate in patients with metastatic prostate cancer].
Zhao JG; Nie L; Chen XQ; Chen N; Zeng H
Zhonghua Wai Ke Za Zhi; 2019 Jun; 57(6):422-427. PubMed ID: 31142066
[No Abstract] [Full Text] [Related]
5. Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer.
Martini A; Gandaglia G; Karnes RJ; Zaffuto E; Bianchi M; Gontero P; Chlosta P; Gratzke C; Graefen M; Tilki D; Cucchiara V; Mirone V; Kneitz B; Sanchez Salas R; Van Der Poel H; Tombal B; Spahn M; Joniau TS; Montorsi F; Briganti A;
Eur Urol Oncol; 2019 Jul; 2(4):456-463. PubMed ID: 31277783
[TBL] [Abstract][Full Text] [Related]
6. Does ductal adenocarcinoma of the prostate (DA) have any prognostic impact on patients with de novo metastatic prostate cancer?
Wu T; Zhao J; Liu Z; Shen P; Zhang M; Sun G; Liu J; Liao B; Chen J; Zhu S; Dai J; Wang Z; Zhang H; Zhao P; Zhang X; Zhu X; Ni Y; Chen N; Zeng H
Prostate; 2019 Oct; 79(14):1673-1682. PubMed ID: 31433509
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer disease recurrence after radical prostatectomy is associated with HLA type and local cytomegalovirus immunity.
Classon J; Zamboni M; Engblom C; Alkass K; Mantovani G; Pou C; Nkulikiyimfura D; Brodin P; Druid H; Mold J; Frisén J
Mol Oncol; 2022 Oct; 16(19):3452-3464. PubMed ID: 35712787
[TBL] [Abstract][Full Text] [Related]
8. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
9. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.
Zhang W; Shu P; Wang S; Song J; Liu K; Wang C; Ran L
Gene; 2018 Oct; 675():136-143. PubMed ID: 29966681
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential.
Bjerre MT; Nørgaard M; Larsen OH; Jensen SØ; Strand SH; Østergren P; Fode M; Fredsøe J; Ulhøi BP; Mortensen MM; Jensen JB; Borre M; Sørensen KD
Cells; 2020 May; 9(6):. PubMed ID: 32486483
[TBL] [Abstract][Full Text] [Related]
11. The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer.
Kim KH; Han KS; Kim KH; Kim DK; Koo KC; Rha KH; Choi YD; Hong SJ
Urol Oncol; 2015 Sep; 33(9):383.e17-22. PubMed ID: 26004165
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of serum CXCL4L1 predicts progression and poor prognosis in prostate cancer patients treated by radical prostatectomy.
Zhang M; Guan J; Huo YL; Song YS; Chen LZ
Asian J Androl; 2019; 21(4):387-392. PubMed ID: 30860083
[TBL] [Abstract][Full Text] [Related]
13. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
[TBL] [Abstract][Full Text] [Related]
14. PSCA, Cox-2, and Ki-67 are independent, predictive markers of biochemical recurrence in clinically localized prostate cancer: a retrospective study.
Kim SH; Park WS; Park BR; Joo J; Joung JY; Seo HK; Chung J; Lee KH
Asian J Androl; 2017; 19(4):458-462. PubMed ID: 27232854
[TBL] [Abstract][Full Text] [Related]
15. rs4143815-
Zanusso C; Dreussi E; Bortolus R; Romualdi C; Gagno S; De Mattia E; Romanato L; Sartor F; Quartuccio L; Cecchin E; Toffoli G
Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31035590
[TBL] [Abstract][Full Text] [Related]
16. Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer.
Schubert M; Spahn M; Kneitz S; Scholz CJ; Joniau S; Stroebel P; Riedmiller H; Kneitz B
PLoS One; 2013; 8(6):e65064. PubMed ID: 23798998
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer.
Wei Y; Wu J; Gu W; Wang J; Lin G; Qin X; Dai B; Gan H; Ye D; Zhu Y
Oncologist; 2020 Jul; 25(7):e1042-e1050. PubMed ID: 32190957
[TBL] [Abstract][Full Text] [Related]
18. Specific spatial distribution patterns of tumor foci are associated with a low risk of biochemical recurrence in pT2pN0R0 prostate cancer.
Eminaga O; Abbas M; Bettendorf O; Semjonow A
World J Urol; 2021 May; 39(5):1499-1507. PubMed ID: 32591903
[TBL] [Abstract][Full Text] [Related]
19. Leukocyte telomere length is associated with aggressive prostate cancer in localized prostate cancer patients.
Xu J; Chang WS; Tsai CW; Bau DT; Xu Y; Davis JW; Thompson TC; Logothetis CJ; Gu J
EBioMedicine; 2020 Feb; 52():102616. PubMed ID: 31981976
[TBL] [Abstract][Full Text] [Related]
20. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.
Zhuo YJ; Xi M; Wan YP; Hua W; Liu YL; Wan S; Zhou YL; Luo HW; Wu SL; Zhong WD; Wu CL
Int J Mol Med; 2015 Apr; 35(4):966-72. PubMed ID: 25647485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
